AgeX Therapeutics

AgeX Therapeutics is a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging. The company is based in Alameda, California, and was founded in 2017.

Overview

AgeX Therapeutics is a subsidiary of BioTime, a clinical-stage biotechnology company. AgeX's mission is to apply technology related to cell immortality and regenerative biology to human aging and degenerative diseases. The company's research and development efforts are primarily focused on developing innovative therapeutics and platforms that can address age-related diseases and conditions.

Technology

AgeX's technology platform includes two major components: PureStem and UniverCyte. PureStem is a proprietary technology for deriving and manufacturing highly-pure progenitor cell lines from pluripotent cells. UniverCyte is a technology based on the use of a novel, modified form of the immune checkpoint inhibitor molecule HLA-G, which can confer immune tolerance to allogeneic cells and tissues.

Therapeutic Programs

AgeX is developing several therapeutic programs based on its technology platform. These include AGEX-BAT1, a cell therapy for metabolic diseases such as Type II Diabetes; AGEX-VASC1, a cell therapy for ischemic diseases; and iTR1547, a drug candidate targeting the telomerase enzyme for potential use in a wide range of age-related diseases.

Partnerships

AgeX has established several strategic partnerships to advance its research and development efforts. These include collaborations with Juvenescence, a biotech company focused on developing therapies that modify aging, and LifeMap Sciences, a subsidiary of BioTime.

See Also

• Biotechnology
• Regenerative Medicine
• Cell Therapy
• Aging